W266418
(S)-(−)-Perillyl alcohol
≥95%, FG
Synonyme(s) :
p-Mentha-1,8-diene-7-ol
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C10H16O
Numéro CAS:
Poids moléculaire :
152.23
FEMA Number:
2664
Council of Europe no.:
2024
UNSPSC Code:
12164502
PubChem Substance ID:
Flavis number:
2.060
NACRES:
NA.21
MDL number:
Organoleptic:
fatty; green
Grade:
FG, Halal, Kosher
Biological source:
synthetic
Food allergen:
no known allergens
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
synthetic
Quality Level
grade
FG, Halal, Kosher
reg. compliance
EU Regulation 1334/2008 & 178/2002, FDA 21 CFR 117, FDA 21 CFR 172.515
assay
≥95%
optical activity
[α]20/D −88°, c = 1 in methanol
refractive index
n20/D 1.501 (lit.)
bp
119-121 °C/11 mmHg (lit.)
density
0.96 g/mL at 25 °C (lit.)
application(s)
flavors and fragrances
documentation
see Safety & Documentation for available documents
food allergen
no known allergens
organoleptic
fatty; green
SMILES string
CC(=C)[C@H]1CCC(CO)=CC1
InChI
1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3/t10-/m1/s1
InChI key
NDTYTMIUWGWIMO-SNVBAGLBSA-N
Application
- CYP108N12 initiates p-cymene biodegradation in Rhodococcus globerulus.: This study explores the enzymatic breakdown pathways of monoterpenes, using (S)-(−)-Perillyl alcohol as a precursor, offering insights into microbial degradation processes that could be vital for bioremediation efforts or synthetic biology applications (Giang et al., 2022).
- Orofacial antinociceptive effects of perillyl alcohol associated with codeine and its possible modes of action.: Research demonstrates the pain-relieving properties of (S)-(−)-Perillyl alcohol when combined with codeine, highlighting its potential for developing new analgesic formulations in dental and facial pain management (Limeira et al., 2022).
- Orofacial antinociceptive activity of (S)-(-)-perillyl alcohol in mice: a randomized, controlled and triple-blind study.: This study underpins the effectiveness of (S)-(−)-Perillyl alcohol in reducing orofacial pain in a controlled experimental setup, providing a basis for further clinical trials in pain management (Tomaz-Morais et al., 2017).
- In Vivo Anti-Tumor Activity and Toxicological Evaluations of Perillaldehyde 8,9-Epoxide, a Derivative of Perillyl Alcohol.: Highlights the anti-tumor properties of a novel derivative of (S)-(−)-Perillyl alcohol, suggesting its potential as a therapeutic agent in oncology, with comprehensive studies on its efficacy and safety (Andrade et al., 2016).
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Classe de stockage
10 - Combustible liquids
wgk
WGK 3
flash_point_f
230.0 °F - closed cup
flash_point_c
110 °C - closed cup
ppe
Eyeshields, Gloves, type ABEK (EN14387) respirator filter
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Contenu apparenté
Eduardo Silva et al.
Pharmaceutics, 12(11) (2020-11-26)
Therapeutic deep eutectic systems (THEDES) have dramatically expanded their popularity in the pharmaceutical field due to their ability to increase active pharmaceutical ingredients (APIs) bioavailability. However, their biological performance has not yet been carefully scrutinized. Herein, THEDES based on the
Ismail Kiran
Natural product communications, 6(12), 1805-1806 (2012-02-09)
S-(-)-Perillyl alcohol (p-mentha-1, 8-diene-7-ol) (1) (500 mg) was converted by Fusarium heterosporium ATCC 15625 over 10 days at 25 degrees C to a new metabolite, 1,2-dihydroxyperillyl alcohol (p-mentha-8-en-1,2,7-triol) (3) in a yield of 13% (70 mg). The structure of 3
Hyun Joo Jung et al.
Blood, 119(11), 2568-2578 (2012-02-02)
Although bortezomib is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this treatment have been demonstrated. To improve survival for bortezomib-resistant patients, it is necessary to develop new therapeutic strategies. In the present study